Acute Interstitial Pneumonitis (AIP)

Acute interstitial pneumonitis (AIP) is also called Hamman–Rich syndrome. Some authors say acute idiopathic interstitial pneumonia or acute idiopathic diffuse alveolar damage (DAD), because the main injury seen under the microscope is diffuse damage to the air sacs. You may also see acute interstitial pneumonia used in place of “pneumonitis.” All these names point to a sudden, severe lung illness that looks like acute respiratory distress syndrome (ARDS), but without a proven outside cause such as infection, toxin, or heart failure. In simple words: AIP is a fast, severe inflammation and injury of the lung tissue with no clear trigger.

Acute interstitial pneumonitis is a rare, life-threatening lung disease. It begins suddenly, often in a healthy person or someone with a recent flu-like illness. The thin walls of the air sacs (alveoli) and the tissue around them (the interstitium) become injured and inflamed. Fluid and proteins leak into the air spaces. This makes large parts of the lungs stiff and heavy with fluid. Because the lungs get stiff, they cannot expand well, and oxygen cannot move easily into the blood. People feel very short of breath and may need oxygen or even a ventilator within days.

Acute interstitial pneumonitis is a sudden, severe inflammation of the lungs that happens without a clear cause. It usually appears in people who were healthy before. In AIP, the tiny air sacs (alveoli) and the supporting tissue around them (interstitium) become swollen and filled with fluid and damaged cells. This makes the lungs stiff, blocks oxygen from entering the blood, and causes fast worsening shortness of breath. AIP looks and behaves like acute respiratory distress syndrome (ARDS), and doctors treat it in similar ways. It is a medical emergency that often needs hospital care, oxygen, and sometimes a breathing machine. AIP can get better with intensive treatment, but it can also be life-threatening. Early recognition, careful support, and protection of the lungs during breathing support are the keys to survival and recovery.

Doctors call AIP “idiopathic,” which means the exact cause is unknown. Before making this diagnosis, they first rule out other problems that can look the same, like severe pneumonia, inhaled toxins, drug reactions, or heart-related fluid in the lungs. On scans, AIP looks like widespread “ground-glass” areas and patchy consolidation. On pathology, it shows diffuse alveolar damage (DAD) with two main phases: an early exudative phase (leakage and hyaline membranes) and a later organizing/fibroproliferative phase (fibroblast growth and scarring). The disease often progresses fast. Some patients recover with supportive care, but many develop respiratory failure. Early recognition and careful intensive care are essential.

---

Types

By pathologic phase. Doctors often describe AIP by the phase seen under the microscope:

• Exudative phase (acute): days 1–7. The capillaries leak fluid and proteins into alveoli. Hyaline membranes line the air spaces. Lungs are very stiff.

• Organizing (proliferative) phase: days 7–21. Fibroblasts grow, and the lung tries to repair. Oxygen transfer is still poor.

• Fibrotic phase (late in some patients): weeks onward. Lasting scarring can remain, which may cause long-term breathlessness.

By clinical pace.

• Fulminant AIP: extremely rapid decline over a few days, often requiring mechanical ventilation.

• Rapidly progressive AIP: over one to two weeks, with severe hypoxemia but sometimes a window for diagnosis and treatment.

These “types” are descriptive, not different diseases. They help explain where the patient is on the injury-to-repair spectrum.

---

Causes

Important note: AIP has no proven single cause. Doctors use this list to exclude other causes of the same lung-injury pattern or to describe possible triggers reported around the time symptoms began. AIP remains the diagnosis only after these are ruled out.

1. Influenza or other viral pneumonia (e.g., RSV, adenovirus): can mimic AIP; must be tested and treated if present.

2. SARS-CoV-2 (COVID-19): causes diffuse alveolar damage similar to AIP; a positive test points to COVID-19 pneumonia, not AIP.

3. Severe bacterial pneumonia or sepsis: widespread infection can cause ARDS; cultures and biomarkers help separate it from AIP.

4. Atypical pathogens (Mycoplasma, Chlamydia, Legionella): special tests are needed; if positive, the process is infectious, not idiopathic.

5. Aspiration of gastric contents: stomach acid inhalation injures alveoli; history of vomiting or reduced consciousness raises suspicion.

6. Inhalation injury (smoke, chlorine, ammonia): toxic gases directly damage the air sacs; exposure history is key.

7. Vaping or oil inhalation exposures: certain oils or additives can harm lungs; if documented, AIP is unlikely.

8. Drug-induced lung injury (e.g., amiodarone, nitrofurantoin, bleomycin, methotrexate, checkpoint inhibitors): medication review is essential.

9. Autoimmune interstitial lung disease flare (e.g., dermatomyositis, rheumatoid arthritis, systemic sclerosis): serology and context matter.

10. Acute eosinophilic pneumonia: looks similar on scans but BAL shows many eosinophils; responds to steroids.

11. Pulmonary edema from heart failure: echocardiogram and BNP help identify cardiac causes of lung fluid.

12. Pulmonary hemorrhage syndromes (e.g., vasculitis): coughing blood and blood in BAL suggest bleeding rather than AIP.

13. Pulmonary embolism with infarction: clots can cause hypoxemia and infiltrates; D-dimer and CT angiography help exclude.

14. Acute hypersensitivity pneumonitis (mold, birds): exposure history plus BAL lymphocytes support this alternate diagnosis.

15. Radiation pneumonitis: prior chest radiation causes inflammation; timing and field of radiation are clues.

16. Pancreatitis-related lung injury: enzymes and inflammation spill over to the lungs during severe pancreatitis.

17. Transfusion-related acute lung injury (TRALI): breathlessness within hours of a blood product points away from AIP.

18. Near-drowning or water aspiration: water in alveoli causes diffuse injury; history reveals the cause.

19. Toxic systemic inflammation (e.g., severe burns, trauma): whole-body inflammation can injure lungs; clinical story fits.

20. Immunodeficiency-related infections (e.g., Pneumocystis): special stains/PCR find organisms; if positive, it is not AIP.

If none of these are present and the pattern fits, doctors may diagnose AIP.

---

Symptoms and signs

1. Sudden shortness of breath: starts over days; simple tasks feel hard.

2. Fast, shallow breathing: the body tries to keep oxygen up as lungs stiffen.

3. Dry cough: often little or no sputum; the problem is in the air sacs.

4. Chest tightness: a heavy, pressure-like feeling with deep breaths.

5. Low oxygen (hypoxemia): dizziness, headaches, or confusion can occur.

6. Bluish lips or fingers (cyanosis): shows very low oxygen in blood.

7. Fever or chills: sometimes present, especially if a viral-like illness occurred before.

8. Severe tiredness and weakness: walking a few steps may be exhausting.

9. Inability to speak full sentences: because each breath brings little oxygen.

10. Rapid heart rate (tachycardia): the heart pumps faster to move limited oxygen.

11. Use of neck and chest muscles to breathe: visible strain with each breath.

12. Sweating and anxiety: the stress of air hunger is intense.

13. Poor sleep due to breathlessness: lying flat may feel worse.

14. Loss of appetite and weight during illness: the body is under high stress.

15. Worsening over days to a week: many patients progress quickly to respiratory failure without support.

---

Diagnostic Tests

Doctors first stabilize breathing and provide oxygen. At the same time, they search for other causes of the same lung injury pattern. They gather a careful history (recent infections, exposures, drugs, transfusions, travel, hobbies, work), perform a focused exam, and order tests. Imaging shows the spread of lung injury. Blood and airway samples look for infection, bleeding, or autoimmune disease. If the patient can safely undergo it, tissue from the lung confirms diffuse alveolar damage. AIP is diagnosed only when no clear outside cause is found and the pattern matches.

Physical exam

1) Vital signs and bedside oxygen check.
Heart rate, breathing rate, blood pressure, temperature, and oxygen saturation show how sick the patient is. Very fast breathing and low oxygen suggest severe lung stiffness and poor gas exchange.

2) Observation of work of breathing.
Doctors watch for chest retractions, nasal flaring, and use of neck muscles. This tells how hard the body is working to pull air in, which correlates with how stiff the lungs have become.

3) Chest auscultation (listening).
Crackles (like Velcro) over both lungs mean fluid and inflammation in many air sacs. Lack of wheeze and the “wet” quality point to an alveolar process rather than asthma.

4) Percussion and tactile fremitus.
Tapping on the chest and feeling vibration while the patient speaks can hint at consolidation. In AIP there may be diffuse dullness where lung units are filled with fluid.

Manual/bedside functional tests

5) Exertional desaturation test (e.g., 1-minute sit-to-stand).
A supervised, very short activity with continuous pulse oximetry can show a sharp drop in oxygen with minimal effort, a common sign of severe diffusion impairment.

6) Six-minute walk test (when stable enough).
Measures distance walked and oxygen trends. In AIP, oxygen often falls quickly; the test is done only if safe and can help track recovery after the acute phase.

7) Incentive spirometry or simple vital capacity check.
Gives a quick sense of how limited the lung volume is. Very low volumes reflect lung stiffness and patient fatigue.

8) Chest expansion measurement with a tape.
Small change in chest circumference between full inhale and exhale suggests restriction and poor lung compliance.

Laboratory and pathological tests

9) Arterial blood gas (ABG).
Directly measures oxygen and carbon dioxide in arterial blood. AIP shows low oxygen (PaO₂) and often low CO₂ from fast breathing, until fatigue causes CO₂ to rise.

10) Complete blood count (CBC).
Looks for infection clues (high white cells) or anemia. While non-specific, it helps separate infection-driven ARDS from idiopathic AIP.

11) Procalcitonin and related inflammatory markers.
Procalcitonin tends to rise in bacterial infections. A low value can support a non-bacterial process and guide antibiotic decisions while other tests return.

12) Microbiology panel (blood and sputum cultures; respiratory PCR).
Finds bacteria and viruses. A positive, clinically relevant result points away from AIP and toward a specific infection that needs targeted therapy.

13) Bronchoscopy with bronchoalveolar lavage (BAL).
Fluid is washed into a small airway and collected. BAL can find organisms, blood (for hemorrhage), eosinophils (for eosinophilic pneumonia), or malignant cells. Typical AIP shows nonspecific inflammation without a dominant infection.

14) Surgical lung biopsy (when feasible and safe).
Wedge samples confirm diffuse alveolar damage with hyaline membranes (exudative phase) and later fibroproliferation. Biopsy is not always possible in unstable patients, but it is the gold standard for diagnosis when uncertainty remains.

Electrodiagnostic/physiologic monitoring

15) Electrocardiogram (ECG).
Rules out heart attack or rhythm problems and supports the distinction between cardiogenic edema and non-cardiogenic lung injury like AIP.

16) Capnography (end-tidal CO₂) during acute care.
Tracks ventilation and helps prevent under- or over-ventilation on oxygen or a ventilator. Rising CO₂ may signal fatigue or worsening failure.

Imaging tests

17) Chest X-ray.
Shows widespread, often symmetrical opacities in both lungs. It is fast and helps follow day-to-day changes, but details are limited.

18) High-resolution CT (HRCT) of the chest.
Key test. Shows diffuse ground-glass and patchy consolidation, usually in many lobes. It helps exclude pulmonary embolism (with contrast), focal abscess, or masses, and it maps severity.

19) Lung ultrasound.
At the bedside, multiple B-lines and poor lung sliding suggest interstitial and alveolar fluid. It is helpful when moving the patient is risky.

20) Echocardiography (heart ultrasound).
Assesses heart function and pressures. A normal left-sided heart with severe lung opacities supports a non-cardiac cause like AIP.

Non-pharmacological treatments

A. Physiotherapy

1. Breathing retraining (diaphragmatic and pursed-lip breathing)
   Description: Guided practice to breathe with the diaphragm and exhale slowly through pursed lips. Sessions are short in the acute phase and longer during recovery.
   Purpose: Reduce breathlessness, improve oxygen levels, and lower the work of breathing.
   Mechanism: Diaphragmatic breathing increases tidal volume with less effort; pursed-lip breathing raises end-expiratory pressure, helping keep airways open and improve gas exchange.
   Benefits: Calmer breathing, less air hunger, better exercise tolerance, and reduced anxiety around breathing.

2. Positioning and prone positioning coaching
   Description: Careful body positions in bed or chair; when supervised in the hospital, time spent lying on the stomach (prone) if recommended.
   Purpose: Improve oxygenation and reduce lung strain.
   Mechanism: Positioning redistributes blood and air in the lungs; prone positioning opens the back areas of the lungs and reduces compression.
   Benefits: Higher oxygen levels, better comfort, and—when used correctly in hospital—lower ventilator stress.

3. Incentive spirometry (post-acute, clinician-guided)
   Description: Using a handheld device to take slow, deep breaths several times a day during recovery.
   Purpose: Reinflate small air sacs and prevent atelectasis after the critical phase.
   Mechanism: Sustained inspiration increases transpulmonary pressure and recruits alveoli.
   Benefits: Improved lung expansion, fewer post-illness complications, better chest comfort.

4. Inspiratory Muscle Training (IMT) during rehabilitation
   Description: Breathing against a set resistance with a trainer device 5–7 days/week once stable.
   Purpose: Strengthen the diaphragm and inspiratory muscles.
   Mechanism: Progressive overload increases muscle endurance and peak inspiratory pressure.
   Benefits: Less fatigue, improved exercise capacity, and easier daily activities.

5. Early mobilization (ICU and ward)
   Description: Safe, stepwise activity—bed exercises, sitting, standing, short ambulation—under supervision.
   Purpose: Prevent deconditioning and blood clots; speed functional recovery.
   Mechanism: Muscle activation and circulation improve oxygen delivery and reduce inflammation markers.
   Benefits: Fewer ICU-acquired weakness issues, faster return to independence.

6. Graded activity pacing
   Description: Planning daily tasks into short, spaced periods with rest to avoid “boom-and-bust” fatigue.
   Purpose: Maintain progress without provoking severe breathlessness.
   Mechanism: Keeps exertion within the person’s ventilatory threshold.
   Benefits: More stable progress, better energy conservation, improved confidence.

7. Airway clearance (when secretions are present)
   Description: Techniques like huff-cough, active cycle of breathing, and gentle chest physiotherapy if clinically indicated.
   Purpose: Move mucus that may worsen gas exchange.
   Mechanism: Controlled expiratory airflow and thoracic expansion mobilize secretions to larger airways.
   Benefits: Easier breathing, fewer small airway blockages, improved oxygenation.

8. Thoracic mobility and postural training
   Description: Gentle stretches for chest wall and shoulders, posture drills to open the rib cage.
   Purpose: Reduce stiffness from bed rest and shallow breathing.
   Mechanism: Improves chest wall compliance and mechanics.
   Benefits: Deeper, less effortful breaths; less neck/shoulder strain.

9. Energy conservation and breathing-while-doing skills
   Description: Teach how to coordinate breathing with movement (exhale on effort), plan tasks, sit for chores.
   Purpose: Reduce dyspnea during daily life.
   Mechanism: Synchronizing breathing with movement lowers ventilatory demand spikes.
   Benefits: More activities done with less breathlessness.

10. Walking reconditioning program
    Description: Structured progression of walking distance and pace, guided by symptoms and oximetry targets set by clinicians.
    Purpose: Restore aerobic capacity safely.
    Mechanism: Gradual cardiovascular and muscular adaptation; improved oxygen extraction.
    Benefits: Better stamina, mood, and sleep.

11. Resistance training (low-to-moderate intensity)
    Description: Light bands or body-weight exercises 2–3 times/week after stabilization.
    Purpose: Rebuild strength lost from illness.
    Mechanism: Muscle hypertrophy and improved metabolic efficiency lower ventilatory equivalent for CO₂ during effort.
    Benefits: Less fatigue, stronger legs for walking, improved quality of life.

12. Cough control and sputum management education
    Description: Timing fluids, humidification, warm showers, and huff technique.
    Purpose: Make coughs productive but less exhausting.
    Mechanism: Optimizes airway hydration and expiratory flow bias.
    Benefits: Less irritation, better sleep, fewer post-tussive desaturations.

13. Pulse-oximeter-guided activity (clinician-recommended)
    Description: Using a pulse-oximeter during rehab with targets provided by the care team.
    Purpose: Keep oxygen saturation in a safe range while active.
    Mechanism: Real-time feedback prevents overexertion and titrates supplemental oxygen if prescribed.
    Benefits: Safer progress, fewer setbacks.

14. Breath stacking with a resuscitation bag (therapist-led)
    Description: Assisted deep breaths to temporarily increase lung volume.
    Purpose: Recruit atelectatic areas after the acute phase when appropriate.
    Mechanism: Incremental insufflations raise alveolar pressure to open closed units.
    Benefits: Improved chest expansion and cough effectiveness.

15. Home safety and recovery ergonomics
    Description: Arrange home to reduce long walks and stairs; sit to perform tasks; use shower chairs.
    Purpose: Limit breathlessness triggers during early recovery.
    Mechanism: Cuts peak oxygen demand during routine activities.
    Benefits: Fewer desaturations, more independence, less fear of activity.

---

B. Mind-body / “gene” / educational therapy

16. Mindfulness-based stress reduction
    Description: Short, daily guided attention exercises and body-scan practice.
    Purpose: Reduce anxiety-driven hyperventilation and air hunger.
    Mechanism: Lowers sympathetic tone and respiratory rate variability.
    Benefits: Calmer breathing, better sleep, improved pain and dyspnea perception.

17. Relaxation breathing with imagery
    Description: 10–15 minute sessions pairing slow breathing with calming mental images.
    Purpose: Break the cycle of panic-dyspnea-faster breathing.
    Mechanism: Parasympathetic activation stabilizes ventilatory drive.
    Benefits: Reduced breathlessness peaks and less fatigue.

18. Sleep hygiene program
    Description: Regular schedule, cool/dark room, limit evening screens/caffeine, side-lying if reflux.
    Purpose: Improve restorative sleep to aid healing.
    Mechanism: Better sleep reduces pro-inflammatory hormones and enhances immune repair.
    Benefits: More energy, clearer thinking, better rehab participation.

19. Education on oxygen use and safety (if prescribed)
    Description: Instruction on flow settings, fire safety, skin care at cannula sites, and travel planning.
    Purpose: Safe and effective oxygen therapy at home.
    Mechanism: Correct use maintains target saturations and prevents harm.
    Benefits: Fewer complications, more mobility and confidence.

20. Vaccination counseling (influenza, pneumococcal, COVID-19 as indicated)
    Description: Teach schedules, boosters, and access points.
    Purpose: Lower risk of severe lung infections during and after recovery.
    Mechanism: Immune priming reduces infection-triggered inflammation.
    Benefits: Fewer setbacks and hospital visits.

21. Nutritional education for lung recovery
    Description: Adequate protein, hydration, and anti-inflammatory food patterns; manage reflux.
    Purpose: Support muscle rebuilding and reduce inflammation.
    Mechanism: Amino acids rebuild tissue; fiber and healthy fats modulate immune signaling.
    Benefits: Better strength and fewer reflux-related coughs.

22. Paced-breathing for exertion anxiety
    Description: Counting breaths (for example 4-in/6-out) before and during tasks.
    Purpose: Keep breathing steady when starting activity.
    Mechanism: Extends exhalation, reduces air-trapping sensation.
    Benefits: Smoother, more confident movement.

23. Smoking and vaping cessation support
    Description: Brief counseling, quit plan, triggers map; referral to programs if needed.
    Purpose: Remove a strong lung irritant.
    Mechanism: Reduces oxidative stress and improves ciliary function.
    Benefits: Better oxygenation, fewer infections, faster healing.

24. Workplace and environment protection coaching
    Description: Reduce exposure to dust, fumes, mold; use masks and ventilation.
    Purpose: Prevent irritation during recovery.
    Mechanism: Lowers inhaled particulates that provoke inflammation.
    Benefits: Fewer flare-ups and symptoms.

25. Clinical-trial literacy (“gene or regenerative” education)
    Description: Explain that no gene therapy is established for AIP; describe how to search reputable trials and discuss with a pulmonologist.
    Purpose: Keep patients safe from unproven stem-cell clinics.
    Mechanism: Informed decision-making using ethics-approved studies only.
    Benefits: Protection from harm and false claims; access to legitimate research when appropriate.

Important note: In the acute phase, physiotherapy is carefully tailored; some techniques (e.g., incentive spirometry, breath stacking) are used only when the care team says it is safe.

---

Drug treatments

1. Methylprednisolone (IV pulse) — Corticosteroid
   Dose/Time: 500–1000 mg IV daily for 3 days, then taper to oral steroids if responding.
   Purpose/Mechanism: Broad anti-inflammatory effect that calms diffuse alveolar damage; reduces capillary leak.
   Benefits/Side effects: May improve oxygenation; risks include high blood sugar, infection, mood changes, myopathy, GI upset.

2. Prednisone (oral taper) — Corticosteroid
   Dose/Time: ~0.5–1 mg/kg/day, then gradual taper over weeks guided by response.
   Purpose/Mechanism: Maintains anti-inflammatory control started with IV pulse.
   Side effects: Weight gain, insomnia, hypertension, osteoporosis, infection risk; needs gastric and bone protection when appropriate.

3. Broad-spectrum antibiotics (e.g., piperacillin-tazobactam) — Antibacterial
   Dose/Time: 4.5 g IV every 6–8 h initially if infection cannot be excluded.
   Purpose/Mechanism: Empiric coverage while ruling out bacterial pneumonia.
   Side effects: Diarrhea, C. difficile, allergic reactions, kidney effects.

4. Azithromycin — Macrolide antibiotic with immunomodulation
   Dose/Time: 500 mg day 1, then 250 mg daily days 2–5 (IV/oral per clinician).
   Purpose/Mechanism: Covers atypicals and may reduce neutrophilic inflammation.
   Side effects: QT prolongation, GI upset, drug interactions.

5. Oseltamivir (if influenza suspected/confirmed) — Antiviral
   Dose/Time: 75 mg orally twice daily for 5 days (renal dosing).
   Purpose/Mechanism: Inhibits neuraminidase to reduce viral replication.
   Side effects: Nausea, rare neuropsychiatric events.

6. Trimethoprim-sulfamethoxazole (if Pneumocystis considered) — Antimicrobial
   Dose/Time: 15–20 mg/kg/day (TMP component) divided 3–4 doses IV or PO.
   Purpose/Mechanism: Inhibits folate metabolism of Pneumocystis jirovecii.
   Side effects: Rash, cytopenias, kidney injury, hyperkalemia.

7. N-acetylcysteine (NAC) — Mucolytic/antioxidant
   Dose/Time: 600 mg orally three times daily (or per protocol).
   Purpose/Mechanism: Replenishes glutathione; may reduce oxidative injury.
   Side effects: Nausea, rare bronchospasm with inhaled forms.

8. Furosemide — Loop diuretic
   Dose/Time: 20–40 mg IV/PO, titrated to fluid balance.
   Purpose/Mechanism: Gentle fluid removal to reduce lung edema while preserving perfusion.
   Side effects: Low potassium, kidney strain, dizziness.

9. Proton pump inhibitor (e.g., omeprazole) — Gastric acid suppression
   Dose/Time: 20–40 mg daily.
   Purpose/Mechanism: Stress-ulcer prophylaxis and GERD control to limit micro-aspiration.
   Side effects: Headache, diarrhea, long-term nutrient effects.

10. Low-molecular-weight heparin (enoxaparin) — Anticoagulant (prophylaxis)
    Dose/Time: 40 mg SC daily (adjust for kidney function).
    Purpose/Mechanism: Prevents blood clots during immobility/critical illness.
    Side effects: Bleeding, bruising.

11. Inhaled nitric oxide (rescue therapy) — Pulmonary vasodilator
    Dose/Time: Typically 5–20 ppm short-term in ICU.
    Purpose/Mechanism: Improves ventilation-perfusion matching; transient oxygenation boost.
    Side effects: Methemoglobinemia, rebound hypoxemia on abrupt stop.

12. Norepinephrine (if shock is present) — Vasopressor
    Dose/Time: ICU infusion titrated to blood pressure goals.
    Purpose/Mechanism: Restores perfusion to vital organs.
    Side effects: Arrhythmias, limb ischemia risk.

13. Cyclophosphamide (select refractory cases; evidence limited) — Immunosuppressant
    Dose/Time: 0.5–1 g/m² IV monthly or 1–2 mg/kg/day PO per specialist.
    Purpose/Mechanism: Dampens exaggerated immune injury when steroid-refractory; case-series level evidence.
    Side effects: Cytopenias, infections, bladder toxicity; specialist oversight required.

14. Mycophenolate mofetil (selected cases) — Immunosuppressant
    Dose/Time: 1–1.5 g orally twice daily.
    Purpose/Mechanism: Inhibits lymphocyte purine synthesis; steroid-sparing in some interstitial lung diseases; evidence in AIP is limited.
    Side effects: GI upset, leukopenia, infection risk, teratogenicity.

15. Antifibrotics (nintedanib or pirfenidone) in post-acute fibrosis patterns—specialist decision
    Dose/Time: Nintedanib 150 mg twice daily; Pirfenidone up-titrated to 801 mg three times daily.
    Purpose/Mechanism: Slow fibroblast activity and collagen deposition; evidence is solid in chronic fibrosing ILDs, uncertain in pure AIP; sometimes considered if persistent fibrotic change emerges.
    Side effects: Diarrhea (nintedanib), photosensitivity and dyspepsia (pirfenidone), liver enzyme elevations.

Reality check: Beyond corticosteroids and meticulous supportive care, high-quality AIP-specific drug evidence is scarce. Many medicines above are used to rule out/treat mimics, manage complications, or are considered case-by-case by specialists.

---

Dietary “molecular” supplements

1. Omega-3 fatty acids (EPA/DHA)
   Dose: 1–2 g/day combined EPA+DHA with meals.
   Function/Mechanism: Precursors to pro-resolving lipid mediators that may dampen inflammatory signaling.
   Note: May thin blood slightly; coordinate with anticoagulants.

2. Vitamin D3
   Dose: 1000–2000 IU/day (or as per blood level).
   Function/Mechanism: Supports innate and adaptive immunity; may reduce infection risk.
   Note: Avoid excess; monitor 25-OH vitamin D.

3. N-acetylcysteine (oral)
   Dose: 600 mg, 2–3×/day.
   Function/Mechanism: Replenishes glutathione; antioxidant support.
   Note: Can cause GI upset.

4. Vitamin C
   Dose: 500 mg, 1–2×/day.
   Function/Mechanism: Antioxidant; cofactor for collagen repair.
   Note: High doses may upset stomach or kidneys in susceptible people.

5. Zinc
   Dose: 15–25 mg elemental zinc/day short term.
   Function/Mechanism: Supports antiviral defense and epithelial repair.
   Note: Long use can lower copper—avoid chronic high doses.

6. Selenium
   Dose: 100–200 mcg/day.
   Function/Mechanism: Part of glutathione peroxidases; reduces oxidative stress.
   Note: Excess is toxic; respect upper limits.

7. Curcumin (with piperine or formulated for absorption)
   Dose: 500–1000 mg/day.
   Function/Mechanism: Modulates NF-κB signaling; anti-inflammatory effects in small studies.
   Note: Interacts with anticoagulants; may cause reflux.

8. Quercetin
   Dose: 500 mg, 1–2×/day.
   Function/Mechanism: Flavonoid with antioxidant and mast-cell-stabilizing actions.
   Note: Limited human lung-specific data.

9. Coenzyme Q10
   Dose: 100–200 mg/day with fat-containing meal.
   Function/Mechanism: Mitochondrial support; may reduce fatigue during rehab.
   Note: Generally well tolerated.

10. Magnesium (glycinate or citrate)
    Dose: 200–400 mg elemental Mg/day.
    Function/Mechanism: Smooth-muscle relaxation; supports sleep and muscle recovery.
    Note: Loose stools with citrate; adjust dose.

---

Immunity booster / regenerative / stem-cell” therapies

These are not standard treatments for AIP. They should only be considered within ethics-approved clinical trials or at specialist advice.

1. Mesenchymal stromal/stem cell (MSCs) infusions
   Dose: Investigational protocols vary.
   Function/Mechanism: Paracrine anti-inflammatory and pro-repair signaling; potential alveolar epithelial support.
   Note: Experimental; unknown long-term risks.

2. GM-CSF (in selected patterns, research use)
   Function: May support alveolar macrophage function in specific lung conditions; not routine for AIP.
   Mechanism: Myeloid cell stimulation.
   Note: Specialist-only, trial context.

3. IL-6 pathway blockade (e.g., tocilizumab) in cytokine-storm phenotypes
   Function/Mechanism: Dampens IL-6–driven inflammation.
   Note: Only in carefully selected cases and trials; infection risk.

4. Antifibrotic-plus-steroid strategy for evolving fibrosis
   Function: Combine anti-inflammatory and anti-fibrotic effects when lungs show persistent scarring patterns.
   Note: Off-label; specialist decision, close monitoring.

5. High-flow nasal cannula with “awake proning” protocol
   Function/Mechanism: Noninvasive oxygenation strategy that may avert intubation.
   Note: Not a drug but often part of “advanced support bundles.”

6. Extracorporeal CO₂ removal (ECCO₂R) as bridge (device therapy)
   Function/Mechanism: Removes CO₂ to allow gentler ventilation.
   Note: Specialized centers only; procedural risks.

---

Procedures/surgeries

1. Bronchoscopy with bronchoalveolar lavage (BAL)
   Procedure: Flexible scope into airways to sample cells and fluid.
   Why: Exclude infections and other mimics; support diagnosis.

2. Video-assisted thoracoscopic surgical (VATS) lung biopsy
   Procedure: Small incisions to remove tiny lung pieces for pathology.
   Why: Confirm AIP pattern (diffuse alveolar damage) when diagnosis is uncertain.

3. Endotracheal intubation and lung-protective mechanical ventilation
   Procedure: Breathing tube and ventilator with low tidal volumes and appropriate PEEP.
   Why: Support oxygen and CO₂ control while lungs heal.

4. Tracheostomy (when prolonged ventilation is expected)
   Procedure: Surgical opening in the neck for a breathing tube.
   Why: Improve comfort, airway care, and mobility during long recovery.

5. Extracorporeal membrane oxygenation (ECMO)
   Procedure: Catheters route blood through an oxygenator outside the body.
   Why: Rescue therapy for severe, reversible respiratory failure.

---

Prevention strategies

1. Keep vaccinations up to date (influenza, COVID-19, pneumococcal as indicated).

2. Do not smoke or vape; avoid secondhand smoke.

3. Reduce exposure to dust, fumes, and molds; use protective masks at work when required.

4. Treat respiratory infections early and follow medical advice fully.

5. Manage reflux (diet, timing of meals, clinician-guided meds) to reduce micro-aspiration.

6. Maintain good fitness with gentle aerobic and strength activity.

7. Eat a balanced, protein-adequate, anti-inflammatory diet; hydrate.

8. Use medicines only as prescribed; avoid unnecessary antibiotics or steroids.

9. Practice hand hygiene and infection-control steps during respiratory virus seasons.

10. Seek medical care promptly for new or worsening shortness of breath.

---

When to see doctors

• Immediately (emergency): Suddenly worsening shortness of breath, blue lips or fingers, confusion, chest pain, inability to speak full sentences, or oxygen saturation < 90% on your usual oxygen.

• Urgently (same day): New fever with cough and breathlessness, fast breathing at rest, drop in home oxygen readings despite rest, or severe fatigue that limits basic tasks.

• Soon (within a week): Persistent cough or breathlessness after a recent lung infection, or if daily activities remain hard after hospital discharge.

• Anytime: Concerns about medicines, side effects, or need for rehab and home oxygen guidance.

---

What to eat and what to avoid

1. Eat: Lean proteins (fish, poultry, legumes) to rebuild muscle.

2. Eat: Colorful vegetables and fruits for antioxidants and fiber.

3. Eat: Whole grains for steady energy during rehab.

4. Eat: Healthy fats (olive oil, nuts, seeds) and foods rich in omega-3s.

5. Eat: Small, frequent meals if large meals worsen breathlessness.

6. Avoid: Smoking, vaping, and exposure to indoor air pollution.

7. Avoid: Very salty, ultra-processed foods that promote fluid retention.

8. Avoid: Heavy late-night meals, spicy foods, and alcohol excess if reflux triggers cough.

9. Avoid: Megadoses of supplements without medical advice, especially if on blood thinners.

10. Hydrate wisely: Enough fluids for mucus clearance unless you are on fluid restriction.

---

Frequently asked questions

1. Is AIP the same as ARDS?
   AIP behaves like ARDS and shows the same lung damage pattern, but the trigger is unknown.

2. Can AIP be cured?
   Many people recover with intensive care, but some develop scarring or have severe illness. Early, expert care matters.

3. Do steroids always work?
   They help many, yet not all. Response varies. Doctors watch closely and adjust care.

4. Why do I need so many tests?
   To rule out infections and other diseases that look like AIP and to guide safe treatment.

5. Will I need a ventilator?
   Some people do, temporarily, to support oxygen while the lungs heal. The team uses gentle, lung-protective settings.

6. What is prone positioning?
   Lying on your stomach under supervision. It can improve oxygen levels by opening up back lung areas.

7. Can I exercise after AIP?
   Yes—slowly and safely. A rehab plan with a therapist helps you rebuild stamina.

8. Do I need oxygen at home?
   Some do for a while. Your team will test you and set targets and safety steps.

9. Are antifibrotic drugs right for me?
   Only if you develop lasting fibrotic changes and your specialist advises it. They are not routine in early AIP.

10. Are stem-cell treatments recommended?
    No, not outside clinical trials. Many commercial offers are unproven and risky.

11. What about vitamins and supplements?
    Some may help as adjuncts, but none replace medical care. Always discuss with your clinician.

12. How long does recovery take?
    It varies. Some improve within weeks; others need months of rehab, especially after ICU stays.

13. Can AIP come back?
    Recurrence is uncommon but possible. Stay in follow-up and act early if symptoms return.

14. Will I have permanent lung damage?
    Some people heal well; others keep some scarring. Pulmonary rehab and healthy living still help function.

15. What can family do to help?
    Support appointments, medication schedules, home safety changes, and encourage gentle activity and good nutrition.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 06, 2025.